Elizabeth Holland


Elizabeth is Global Co-Head of IP Litigation.

She is a first-chair trial lawyer who focuses exclusively on representing innovators in patent infringement and related litigation in the life sciences space. With over 35 years of experience, Elizabeth has served as lead counsel in numerous patent infringement litigations, licensing disputes, arbitrations, IPR proceedings and Federal Circuit appeals. She has particular expertise in Hatch-Waxman and BPCIA litigation, as well as disputes between innovator companies.

Elizabeth is consistently ranked among the top lawyers in her field by publications such as Chambers Global, Chambers USA, IAM 1000 – The World's Leading Patent Practitioners, The Legal 500 U.S., Managing Intellectual Property, LMG Life Sciences and Euromoney, which have noted her “assured handling of even the most complex pharmaceuticals patent cases” and have described her as “exactly what you want in a first-chair lawyer; she is very skilled in the courtroom, very adept at managing multiple important cases, and well-liked by judges.”

Elizabeth has also been noted as being “exceptional on her feet in court;” getting “excellent results;” and “understanding clients’ business goals and litigating with those in mind.” She has thrice been named “Hatch Waxman Litigator of the Year” by LMG Life Sciences and has been featured as a “Winning Litigator” by the National Law Journal.

Elizabeth has successfully represented companies such as Novartis, Takeda, Wyeth, Celltrion, Ceva Sante, Enzymotec, and Boston Scientific in patent litigation in district courts throughout the United States, at the International Trade Commission, in post-grant proceedings before the PTAB, and at the Federal Circuit. She has also coordinated worldwide patent litigation, and has particular experience with courts in the UK, Netherlands, France, Israel, India and Mexico. 

At her previous firms, Elizabeth served on the Executive, Management, and Partnership committees and chaired the Diversity, Equity + Inclusion Committee.

Leadership Positions And Professional Affiliations

  • Member, American Bar Association
  • Member, American Intellectual Property Association
  • Member New York Intellectual Property Association
  • Member, New York City Bar Association
Brilliant strategist on complex technical and legal issues.
Chambers Global USA Intellectual Property: Patent, 2021
She has excellent instincts, is sharp and intuitive and has an innate ability to understand a pharmaceutical client's business.
Chambers Global USA Intellectual Property: Patent, 2021


  • Leading practitioner for Life Sciences in U.S., Women in Business Law, Expert Guides, 2022
  • Patent Star, 2021-2022, Managing Intellectual Property IP Stars
  • Band 2, Chambers USA Life Sciences: IP/Patent Litigation - Nationwide, 2022
  • Band 2, Chambers USA Intellectual Property: Patent - New York, 2022
  • Top 250 Women in IP, Managing Intellectual Property, 2022
  • Gold Band, IAM 1000 – The World's Leading Patent Practitioners, 2021
  • 2x Winner, LMG Life Sciences Awards Hatch-Waxman Litigator of the Year
  • WIPR Leaders, 2021
  • Top 250 Women in Litigation, Benchmark Litigation
  • Top 50 Women in PTAB Trials, PTAB Bar Association
  • Top 10% of practitioners (of more than 5,000 lawyers), Patexia IPR Intelligence Report
  • Past recipient, Euromoney Women in Business Law Best in Life Sciences Award 



Registered Foreign Lawyer, England and Wales, 2024

Admitted to the Bar of the State of New York, 1989

U.S. Patent and Trademark Office (USPTO), 2001

U.S. District Court for the Eastern District of New York

U.S. District Court for the Southern District of New York

U.S. Court of Appeals for the Federal Circuit

U.S. Supreme Court


JD, Benjamin N. Cardozo School of Law, magna cum laude, 1988

BS (Chemical Engineering), The Cooper Union, 1985

A&O Shearman was formed on May 1, 2024 by the combination of Shearman & Sterling LLP and Allen & Overy LLP and their respective affiliates (the legacy firms). Any matters referred to above may include matters undertaken by one or more of the legacy firms rather than A&O Shearman.